Four Palestinians were killed in a feud between two families allied with political rivals Hamas and Fatah, raising concerns about a new outbreak of factional fighting.
Saturday was the deadliest day in Gaza since Hamas and Fatah reached a power-sharing deal two weeks ago. That agreement halted months of bloody clashes, but Gaza remains volatile because families of some of those killed still seek revenge.
The latest fighting erupted in the southern town of Khan Younis, between the Ghelban clan allied with Hamas and the Karouah family, which is linked to Fatah. Both families sustained casualties in recent months of fighting.
Just before midnight on Friday, Mohammed Ghelban, 28, a local commander of Hamas' military wing, was driving in his car with his wife and children, said a local security official. Assailants dragged Ghelban from his car and shot and killed him in front of his family, the official said. It was not immediately clear what prompted the attack.
A member of the rival clan, 22-year-old Hazem Karouah, 22, was killed several hours later, as was 75-year-old Ismail Sabah, who was caught in the line of fire. Later on Saturday, 27-year-old Ghada Karouah died of gunshot wounds.
Thirty-seven people were wounded, including four who were in critical condition, hospital officials said.
The two factions did not openly blame each other. However, government spokesman Ghazi Hamad of Hamas said some groups were "trying to revive the internal conflict through acts of aggression."
Talal Okal, a Palestinian commentator, said that the family feuds "are part of the rubble left over from the fighting." However, he said he expected Hamas and Fatah to try to suppress revenge attacks in order not the endanger the power-sharing agreement.
The COVID-19 variant discovered in South Africa can “break through” Pfizer-BioNTech’s COVID-19 vaccine to some extent, a real-world data study released on Saturday found, although its prevalence in the country is low and the research has not been peer reviewed. The study in Israel compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated people with the disease. It matched age and gender, among other characteristics. The South African variant, B.1.351, was found to make up about 1 percent of all the COVID-19
RARE ADMISSION: A top Chinese expert was the first to publicly address the efficacy of the nation’s vaccines as it aims to inoculate 40 percent of its population by June China is considering mixing different COVID-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert told a conference in Chengdu on Saturday. Authorities have to “consider ways to solve the issue that efficacy rates of existing vaccines are not high,” Chinese media outlet The Paper reported, citing Chinese Center for Disease Control and Prevention Director Gao Fu (高福). His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country’s vaccines, as China forges ahead in its mass vaccination campaign and exports its jabs around the world. China
The Australian government yesterday said that it had decided against buying the single-dose Johnson & Johnson (J&J) COVID-19 vaccine and identified a second case of a rare blood clot likely linked to the AstraZeneca shot. The Australian government had been in talks with the New Jersey-based pharmaceutical giant, which had asked the Australian Therapeutic Goods Administration for provisional registration. However, Australian Minister of Health Greg Hunt ruled out a J&J contract, because its vaccine was similar to the AstraZeneca product, which Australia had already contracted for 53.8 million doses. Hunt said the government was following the advice of Australia’s scientific and technical advisory
The Indonesian government has said it is satisfied with the effectiveness of the Chinese COVID-19 vaccine it has been using, after China’s top disease control official said that current vaccines offer low protection against the novel coronavirus. Siti Nadia Tarmizi, a spokesperson for Indonesia’s COVID-19 vaccine program, on Monday said the WHO had found that the Chinese vaccines had met requirements by being more than 50 percent effective. Clinical trials in Indonesia for the vaccine from Chinese drugmaker Sinovac showed that it was 65 percent effective, she said. “It means ... the ability to form antibodies in our bodies is still very